Contact VaxLiant:

800-533-8617 info@vaxliant.com

Swine

ENABL adjuvants

Five formulations are regulatory-ready for subcutaneous and intramuscular administration in pigs, and available for your evaluation.

What makes ENABL swine adjuvants unique?

  • The polymer carrier stabilizes the emulsion, with release managed using a polymer matrix and by adjusting pH
  • The amphipathic lipid component mimics bilaminar membrane characteristics and, in combination with the polymer, provides adhesive features
  • The cell-fusion component augments binding to cells
  • The membrane-activating agent stimulates cells
  • They accommodate unmatched flexibility in delivery (size and adherence), stability and measurable recovery

ENABL swine adjuvants enable:

  • in vitro screening
  • Similar effectiveness using less antigen
  • Ability to recover antigen for product-release assays
  • Stimulation of different immune responses
  • Different formulations (e.g., DNA, gene vector, subunit, modified-live virus, killed virus)
  • Different routes of inoculation
  • Protection with a single dose
  • Improved stabilization
  • A stronger immune response
  • Ability to meet product-approval safety and withdrawal requirements

Read an overview of the research supporting our novel swine adjuvants.

ENABL Safety Data Sheet